Alexander E. Abolmasov

Alexander E. Abolmasov

Auto-generated profile, based on publicly available information

Alexander E. Abolmasov

University Headache Clinic (Dr. Laskov's Clinic)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
VEVladimir Evdokimov
Vladimir Evdokimov
ABAnatoly A. Bloshchinenko
Anatoly A. Bloshchinenko
AAAlexander E. Abolmasov
Alexander E. Abolmasov
AVAlexey A. Vilensky
Alexey A. Vilensky
MLMichail S. Laskov
Michail S. Laskov
ВАВиленский Алексей Александрович
Виленский Алексей Александрович
Aim. To evaluate the effectiveness of trastuzumab deruxtecan in real-world practice in the Russian Federation. Materials and methods. We performed a retrospective analysis of clinical case series related to the use of trastuzumab deruxtecan (N=15) in the setting of a single clinical center, University Headache Clinic (Dr. Laskov's Clinic), as part of the program for the import of an unapproved drug as a life-saving measure. The overall survival, progression-free survival, and objective response rate were assessed, and individual real-world cases of drug efficacy were presented. Results. Objective response rates are comparable to those shown in large randomized trials. The median follow-up was 67 days; the 6-month overall survival was 70.1% (95% confidence interval [CI] 49.4–99.6%), and the 6-month progression-free survival was 52.1% (95% CI 29.9–90.6%). There were no significant complications associated with therapy; in particular, no events of interstitial lung disease were reported. Discussion. The real-world efficacy of trastuzumab deruxtecan was comparable to that in randomized clinical trials. However, at the level of individual clinical cases, slightly lower efficacy was noted in initially frailer patients (ECOG score 3). Also, it should be noted that the study included patients who had the opportunity to purchase an expensive drug and, therefore, had a social status different from the general population, which could affect the results of this study. Conclusion. The use of trastuzumab deruxtecan in real-world settings has demonstrated high efficacy and a good safety profile.